Lausanne, Switzerland, March 31, 2025 – Novigenix, a leader in AI-driven precision liquid biopsy solutions, has been awarded EUR 1.8M through the new BRECISE IHI grant funded by the European Union (EU) research initiative focusing on revolutionizing cancer diagnostics, treatment, and monitoring through advanced multi-omics and artificial intelligence.

The BRECISE consortium was launched last week in Madrid at its face-to-face kick-off meeting during the 40th meeting of the European Association of Urology Congress. The multi-stakeholder collaborative effort, co-funded by the Innovative Health Initiative (IHI) under the Horizon Europe program, aims to transform patient care by integrating Next-Generation Sequencing (NGS)-based biomarkers with AI-driven decision-making frameworks.

BRECISE seeks to address critical challenges in oncology, particularly in prostate and bladder cancer, by accelerating the clinical validation of multi-modal biomarkers.

Brian Hashemi, CEO of Novigenix, said: “Our participation in BRECISE marks another major milestone in our mission to improve patient outcomes through data-driven precision oncology. Our contribution is to bring the expertise we have built over a decade of developing AI-powered liquid biopsy solutions, including LITOSeek™, which provides unparalleled predictive insights into immune response to tumor biology, and therapy resistance through the integration of transcriptomic and genomic biomarkers with advanced AI modelling.”

Current oncology programs struggle with accurate prediction of patient response, often leading to suboptimal treatment and poor patient outcomes. By integrating whole blood RNA sequencing with circulating tumor DNA (ctDNA) analysis, Novigenix’s LITOSeek™ platform provides unprecedented level prediction of clinical benefit providing next generation liquid biopsy for:

  • Better patient stratification: identifying responders and non-responders to specific therapies with increased precision.
  • Improved adverse event prediction: reducing treatment-related complications by enhancing risk assessment.
  • Optimized drug development: supporting biopharma partners in selecting the right patient populations for clinical trials, improving efficiency and success rates.

Dr. Ralf Hoffmann, Principal at Philips Research and industry project leader for BRECISE, said: “BRECISE represents a paradigm shift in precision oncology and cancer care. By using advanced NGS technologies and AI integration to validate biomarker models, we can enable personalized treatment for prostate and bladder cancer patients. This approach not only improves patient outcomes but also optimizes healthcare resources by guiding more accurate and efficient treatment decisions. BRECISE is bringing the future of cancer care into the present.”

Dr. Pedro Romero, Chief Medical and Scientific Officer at Novigenix, added, “Participating in BRECISE aligns with our mission to drive innovation in precision oncology. By integrating multi-modal biomarkers with AI-powered analytics, we can significantly improve therapeutic decision-making, offering a real opportunity to personalize treatment strategies and enhance patient outcomes.”

For over a decade, Novigenix has been at the forefront of AI-powered liquid biopsy solutions. Through continuous innovation, the company has developed an ISO 13485-certified AI analytics platform that empowers biopharma companies with novel biomarker discovery, immune profiling, and predictive modelling capabilities. The BRECISE initiative strengthens Novigenix’s positioning as a pivotal player in the AI-driven healthcare landscape, reaffirming its commitment to harnessing technology to de-risk drug development and accelerate the adoption of precision medicine.